Nobody has measured how long 7-OH from concentrated products stays in the body. The best human data come from kratom leaf studies, where 7-OH had a half-life of about 5 hours after one dose and about 25 hours after two weeks of daily use. Standard drug panels do not look for it; specialised kratom tests can.1,2
That leaves a lot of uncertainty. Half-life is not the same as a detection window, the few human studies used leaf or extract rather than the tablets, shots and films now sold as 7-OH, and urine and hair windows for 7-OH have never been established in controlled studies.
This guide sets out what the pharmacokinetic studies show, what laboratories can detect in blood, urine and hair, how standard opioid panels differ from kratom-specific tests, and which factors change the picture. It is not a guide to passing a test. If you are worried about a test because you are dependent on 7-OH, that is a reason to talk to a clinician.
At a glance
| Question | What the evidence shows |
|---|---|
| Half-life (leaf, single dose) | Mean of up to 4.7 hours1 |
| Half-life (leaf, 15 daily doses) | Mean of up to 24.7 hours1 |
| Time to peak blood level | About 1.2 to 2.3 hours after swallowed leaf or extract1,3 |
| Concentrated 7-OH products | No published human pharmacokinetic data |
| Standard 5- or 10-panel test | Not included in the federal urine panel2 |
| Kratom-specific test | LC-MS/MS methods detect 7-OH in urine and blood4,5 |
| Hair | Detected in some research samples, missed in others6,7 |
| Established detection window | None for any sample type |
What 7-OH is and how the body handles it
7-hydroxymitragynine is a minor alkaloid in kratom and a metabolite of mitragynine, the plant’s main alkaloid. In a 2024 study of healthy volunteers given kratom tea, blocking the enzyme CYP3A4 with itraconazole cut 7-OH exposure by about 43 to 56%, the first direct evidence that people convert mitragynine into 7-OH through that enzyme.8 In that study 7-OH peaked at about 1.8 hours, and its total exposure was about a fifth of mitragynine’s.8
Concentrated products change that relationship. Semi-synthetic 7-OH tablets, shots and films deliver the compound directly, and some are designed for under-the-tongue or nasal use, routes that avoid first-pass liver metabolism and speed onset.9,10 A 2026 review of these non-swallowed products found no clinical, safety or pharmacokinetic data for them at all.10 For the background chemistry, see our explainer on mitragynine vs 7-hydroxymitragynine and our overview of how 7-OH products differ from traditional kratom.
7-OH half-life: what the human studies show
Human blood data for 7-OH come from a few controlled studies of leaf, tea or extract, plus one case report from inside a clinical trial.
| Study | What was given | Key 7-OH finding |
|---|---|---|
| Huestis et al., 20241 | 500 to 4,000 mg leaf powder, single and 15 daily doses | Peak at 1.2 to 2.0 hours; mean half-life up to 4.7 h (single) and 24.7 h (multiple); steady state within 7 days |
| Huestis et al., 20263 | Kratom extract, 9.9 to 59.2 mg mitragynine | Peak at 1.3 to 2.3 hours; higher 7-OH to mitragynine ratios after repeated doses; signs of possible enzyme saturation |
| Mongar et al., 20248 | Kratom tea, 23.6 mg mitragynine | Peak 12.8 ng/mL at 1.8 hours; blood sampled for 72 hours |
| Smith et al., 202511 | Trial participant who had also used a 7-OH product | 7-OH peaked at 11.7 ng/mL before he took the study kratom, showing recent 7-OH product use |
The pattern matters. 7-OH clears faster than mitragynine, whose mean half-life reached 43.4 hours after one dose and 67.9 hours after repeated dosing in the same 2024 study.1 An earlier Thai study of nine chronic kratom users put mitragynine’s terminal half-life at about 23 hours, with wide variation between people.12 So 7-OH may become undetectable before mitragynine does, which is one reason a test that looks only for mitragynine can tell a misleading story.
The jump in 7-OH half-life with repeated dosing is also important. It suggests that someone who uses daily may carry 7-OH for longer than single-dose figures imply, although those results come from leaf, not from concentrated products.
Half-life is not a detection window
A half-life is the time for the blood level to fall by half. Simple arithmetic shows why it is only a starting point: after five half-lives about 3% of the peak level remains, which works out to roughly a day for a 4.7-hour half-life and about five days for a 24.7-hour one. Whether that remainder is detectable depends on the starting dose, the test’s cut-off, the sample type and how the lab handles it, none of which the arithmetic captures. Animal data add another wrinkle. In rats, swallowed 7-OH was absorbed quickly but had an oral bioavailability of only 2.7%.13 Human figures for 7-OH products are not available.
How long does 7-OH stay in urine, blood and hair?
No study has followed people after a known dose of a 7-OH product and tested them until they turned negative. What laboratory research does show is below.
| Sample | What is known | What is not known |
|---|---|---|
| Blood or plasma | Measured for 72 hours after kratom tea; levels fall fastest of all sample types8 | Window after 7-OH tablets, shots or films |
| Urine | 7-OH found in 63% of unhydrolysed urine samples from kratom cases; validated LC-MS/MS methods monitor it5,4 | How many days after last use it stays positive |
| Hair | Found at 0.34 to 15 pg/mg in six Korean samples with a very sensitive method, but not detected in 91 hair sections from a 3 g/day kratom user with a less sensitive one6,7 | Whether hair reliably shows 7-OH product use |
| Post-mortem samples | Mitragynine-to-7-OH ratios averaged about 31 in blood and 17 in urine in 51 cases14 | How ratios differ after semi-synthetic products |
Two laboratory issues make 7-OH harder to measure than many drugs. In stored samples, 7-OH was stable for about 7 days under refrigeration, and levels had dropped by more than half after 60 days, while mitragynine was stable for 30 days.14 And in human plasma in the lab, 7-OH converts into mitragynine pseudoindoxyl, a more potent opioid, something not seen to the same extent in other species.15 Both findings can affect what a test reports. Research on 7-OH and the blood-brain barrier adds a further point: blood levels do not map neatly onto brain levels, because in rats both alkaloids undergo extensive efflux at the barrier.16
Standard opioid panels vs kratom-specific tests
The federal workplace urine panel covers marijuana, cocaine, codeine, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, 6-acetylmorphine, PCP, fentanyl and the amphetamines. Kratom, mitragynine and 7-OH are not on it.2 Opiate immunoassays are built around morphine-type structures. In one published case where mass spectrometry confirmed five kratom alkaloids in urine, the opiate immunoassay was negative,17 although no study has tested 7-OH products specifically against these screens. Our guide to whether kratom shows up on a drug test covers immunoassay cross-reactivity in more detail.
Kratom-specific testing is different. Liquid chromatography with tandem mass spectrometry (LC-MS/MS) can quantify mitragynine and monitor 7-OH and other metabolites in urine at low nanogram levels.4 These tests have to be requested specifically; the published method has been used in clinical and forensic work.4
There is a catch for 7-OH products. Clinicians reporting a case of dependence on a semi-synthetic 7-OH film warned that standard laboratory testing can detect mitragynine but not 7-OH, because of its shorter half-life, and that this can make 7-OH use look like ordinary kratom use.9 In other words, a negative or “kratom only” result does not rule out recent 7-OH product use.
Factors that change how long 7-OH is detectable
- Amount and frequency. 7-OH peak levels rose with dose, and its half-life was roughly five times longer after 15 daily doses than after one.1
- Product type and route. Concentrated products bypass the body’s own conversion step and produce much higher 7-OH exposure than leaf,18 and products vary widely: the DEA reports 7-OH products ranging from 1 mg to 700 mg.19
- Liver enzymes and other medicines. CYP3A4 activity shapes how much 7-OH forms from mitragynine, and an enzyme-blocking drug cut 7-OH exposure substantially.8 Liver disease and interacting drugs could plausibly change clearance too, but this has not been studied for 7-OH products. See our guide to kratom and drug interactions.
- Body composition. Mitragynine has a very large volume of distribution, suggesting extensive spread into tissues.12 Whether body fat lengthens 7-OH detection has not been tested.
- The test itself. Sample type, cut-off, which analytes are targeted and how long the sample is stored all affect the result.14,9
What this means if you use 7-OH
The honest answer to “how long does 7-OH stay in your system” is that the drug itself probably clears from blood within a day or so after occasional use and more slowly with daily use, but nobody can give a reliable detection window. Anyone who needs certainty, for work, treatment or legal reasons, should not rely on estimates from leaf studies.
The shorter half-life also has a downside: it is linked to faster-onset withdrawal when daily use stops. Our guide to 7-OH withdrawal symptoms and timeline explains what case reports show and how people get help. With federal scheduling of 7-OH above a set threshold possible from 13 November 2026, a conversation with a clinician now is better than an unplanned stop later.19 The free, confidential SAMHSA National Helpline is on 1-800-662-4357, 24 hours a day.20 Our explainer on where 7-OH scheduling stands covers the legal detail.
Frequently asked questions
How long does 7-OH stay in your system?
No study has measured it for concentrated 7-OH products. In controlled kratom leaf studies, 7-OH had a mean half-life of up to about 5 hours after one dose and about 25 hours after 15 daily doses.1 That suggests blood levels fall quickly after occasional use and more slowly with daily use, but detection windows for urine, blood or hair have not been established.
Does 7-OH show up on a standard drug test?
Not on a standard workplace panel. The federal urine panel tests for drugs such as morphine, oxycodone, fentanyl and amphetamines, and does not include kratom alkaloids.2 Laboratories can detect 7-OH with specialised LC-MS/MS tests, which are ordered deliberately, usually in treatment, pain management, emergency or forensic settings.4
Will 7-OH make me test positive for opiates?
It is not expected to, but this has not been tested directly. Opiate immunoassays target morphine-like structures, and 7-OH is a structurally different indole alkaloid even though it acts on the mu-opioid receptor. In a published kratom case, the opiate screen was negative while mass spectrometry found kratom alkaloids.17 Any unexpected positive screen should be confirmed by mass spectrometry.
Can a kratom test tell 7-OH tablets apart from kratom leaf?
Not reliably. Tests report concentrations of mitragynine, 7-OH and metabolites, not product type. Clinicians have warned that standard testing can detect mitragynine but miss 7-OH because it clears faster, which can make semi-synthetic 7-OH use look like ordinary kratom use.9 Telling your clinician what you actually take is more reliable than any test.
What is the half-life of 7-hydroxymitragynine?
In a 2024 controlled study of dried kratom leaf powder, the highest mean 7-OH half-life was 4.7 hours after a single dose and 24.7 hours after 15 daily doses, against 43.4 and 67.9 hours for mitragynine.1 No equivalent figures have been published for semi-synthetic 7-OH tablets, shots or films, so those numbers may not apply to them.
Sources
- Huestis MA, Brett MA, Bothmer J, Atallah R. Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder. Molecules. 2024;29(5):984. DOI: 10.3390/molecules29050984. PMID: 38474495. pubmed.ncbi.nlm.nih.gov
- Substance Abuse and Mental Health Services Administration. Mandatory Guidelines for Federal Workplace Drug Testing Programs: Authorized Testing Panels. 91 FR 12308. 13 March 2026. federalregister.gov
- Huestis MA, Brett MA, Bothmer J, Henningfield JE, Swift S. Mitragynine and 7-hydroxy-mitragyine plasma pharmacokinetics in humans after single and 15 multiple oral kratom extract doses. J Anal Toxicol. 2026;50(6). DOI: 10.1093/jat/bkag042. PMID: 42266029. pubmed.ncbi.nlm.nih.gov
- Le D, Goggin MM, Janis GC. Analysis of mitragynine and metabolites in human urine for detecting the use of the psychoactive plant kratom. J Anal Toxicol. 2012;36(9):616-625. DOI: 10.1093/jat/bks073. PMID: 23024321. pubmed.ncbi.nlm.nih.gov
- Basiliere S, Kerrigan S. Identification of metabolites and potential biomarkers of kratom in urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1140:121971. DOI: 10.1016/j.jchromb.2020.121971. PMID: 32058315. pubmed.ncbi.nlm.nih.gov
- Rhee J, Shin I, Kim J, Lee J, Cho B, Kim J, et al. LC-MS-MS method for mitragynine and 7-hydroxymitragynine in hair and its application in authentic hair samples of suspected kratom abusers. J Anal Toxicol. 2024;48(6):429-438. DOI: 10.1093/jat/bkae041. PMID: 38780234. pubmed.ncbi.nlm.nih.gov
- Meier U, Mercer-Chalmers-Bender K, Scheurer E, Dussy F. Development, validation, and application of an LC-MS/MS method for mitragynine and 7-hydroxymitragynine analysis in hair. Drug Test Anal. 2020;12(2):280-284. DOI: 10.1002/dta.2746. PMID: 31833662. pubmed.ncbi.nlm.nih.gov
- Mongar P, Jaisi A, Inkviya T, Wungsintaweekul J, Wiwattanawongsa K. Effects of Itraconazole on Pharmacokinetics of Mitragynine and 7-Hydroxymitragynine in Healthy Volunteers. ACS Pharmacol Transl Sci. 2024;7(3):823-833. DOI: 10.1021/acsptsci.3c00335. PMID: 38481700. pubmed.ncbi.nlm.nih.gov
- Reif B, Adkins A, Boyer EW, Kanumuri SRR, Sharma A, Smith KE. Substance Use Disorder Following Consumption of a Novel Synthetic 7-Hydroxymitragynine Product. J Addict Med. 2025 (published online 5 November 2025). DOI: 10.1097/ADM.0000000000001603. PMID: 41189061. pubmed.ncbi.nlm.nih.gov
- White CM, Sedensky A, Belcourt J, Kulkarni P. Nonswallowed Kratom-Derived Products: Unlawful Dietary Supplements That Endanger Public Health. Public Health Rep. 2026;141(3):335-338. DOI: 10.1177/00333549251410520. PMID: 41587771. pubmed.ncbi.nlm.nih.gov
- Smith KE, Rama Raju Kanumuri S, Sharma A, Rattenni R, LeComte R, McCurdy CR, et al. Complicating Factors Surrounding Concurrent Use of Kratom and a Novel 7-hydroxymitragynine Product Among a Participant Enrolled in a Kratom Clinical Trial. J Addict Med. 2025 (published online 31 October 2025). DOI: 10.1097/ADM.0000000000001604. PMID: 41177541. pubmed.ncbi.nlm.nih.gov
- Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421-2429. DOI: 10.2147/DDDT.S79658. PMID: 25995615. pubmed.ncbi.nlm.nih.gov
- Chiang YH, Kanumuri SRR, Kuntz MA, Senetra AS, Berthold EC, Kamble SH, et al. In Vitro and In Vivo Pharmacokinetic Characterization of 7-Hydroxymitragynine, an Active Metabolite of Mitragynine, in Sprague-Dawley Rats. Eur J Drug Metab Pharmacokinet. 2025;50(3):205-218. DOI: 10.1007/s13318-025-00939-2. PMID: 40119246. pubmed.ncbi.nlm.nih.gov
- Osawa KA, Johnson RD. Postmortem distribution of mitragynine and 7-hydroxymitragynine in 51 cases. J Anal Toxicol. 2025;49(2):122-128. DOI: 10.1093/jat/bkae099. PMID: 39777518. pubmed.ncbi.nlm.nih.gov
- Kamble SH, León F, King TI, Berthold EC, Lopera-Londoño C, Siva Rama Raju K, et al. Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy. ACS Pharmacol Transl Sci. 2020;3(6):1063-1068. DOI: 10.1021/acsptsci.0c00075. PMID: 33344889. pubmed.ncbi.nlm.nih.gov
- Yusof SR, Mohd Uzid M, Teh EH, Hanapi NA, Mohideen M, Mohamad Arshad AS, et al. Rate and extent of mitragynine and 7-hydroxymitragynine blood-brain barrier transport and their intra-brain distribution: the missing link in pharmacodynamic studies. Addict Biol. 2019;24(5):935-945. DOI: 10.1111/adb.12661. PMID: 30088322. pubmed.ncbi.nlm.nih.gov
- Arndt T, Claussen U, Güssregen B, Schröfel S, Stürzer B, Werle A, et al. Kratom alkaloids and O-desmethyltramadol in urine of a “Krypton” herbal mixture consumer. Forensic Sci Int. 2011;208(1-3):47-52. DOI: 10.1016/j.forsciint.2010.10.025. PMID: 21112167. pubmed.ncbi.nlm.nih.gov
- Alsbrook S, Pro G, Koturbash I. From kratom to 7-hydroxymitragynine: evolution of a natural remedy into a public-health threat. Pharm Biol. 2025;63(1):896-911. DOI: 10.1080/13880209.2025.2590311. PMID: 41275505. pubmed.ncbi.nlm.nih.gov
- Drug Enforcement Administration. Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I. 91 FR 65370, FR Doc. 2026-20943, Docket DEA-1570. 14 October 2026. federalregister.gov
- Substance Abuse and Mental Health Services Administration. SAMHSA’s National Helpline. samhsa.gov
This article is for educational purposes only and is not medical or legal advice. Products discussed here are not intended to diagnose, treat, cure or prevent any disease. Laws vary by location and change often, so verify the rules that apply where you are. Always talk to a licensed healthcare provider before use, especially if you are under 21, pregnant or nursing, taking medication, or managing a health condition.